DAVID HELLERSTEIN, MD         PSYCHIATRY   PRACTICE   RESEARCH   OFFICE LOCATION   PRACTICE POLICIES   ABOUT DR.      HELLERSTEIN   LINKS WRITING     BOOKS     LITERARY WRITING     ABOUT DAVID        HELLERSTEIN     PUBLICATIONS     EXCERPTS     LINKS    Books available at:        Amazon.com        Backinprint.com   E-Mail Contact:   djhell@aol.com Mailing Address:   Beth Israel Medical Ctr.    1st Ave & 16th St.    New York, NY 10003

© 1999, David Hellerstein   David Hellerstein, M.D.              Psychiatrist and Writer RESEARCH                  Dr. Hellerstein is Director of the Mood Disorders Research Unit at Beth Israel Medical Center. This research center enrolls subjects for studies on a variety of medications, both established and new treatments. It has participated in pioneering studies in areas including: · the treatment of dysthymia (chronic depression), · the treatment of bipolar depression and bipolar mania, · the combination of psychotherapy and pharmacotherapy for treatment of depression SCIENTIFIC PUBLICATIONS Dr. Hellerstein has published over 30 articles and book chapters, and over 40 abstracts in scientific journals and professional organizations proceedings. Journals include: American Journal of Psychiatry, Archives of General Psychiatry, Journal of Psychotherapy Practice and Research, Hospital and Community Psychiatry, Journal of Serotonin Research, Progress in Neuropsychopharmacology and Biological Psychiatry, Journal of Clinical Psychiatry, and CNS Drugs. Dr. Hellerstein has made many presentations at national and international conferences. SELECTED SCIENTIFIC PUBLICATIONS 1) Hellerstein D, Meehan B: Outpatient group therapy for schizophrenic substance abusers. American Journal of Psychiatry 1987;144:1337-40 2) Rosenthal RN, Hellerstein DJ, Miner CR: A model of integrated services for outpatient treatment of patients with comorbid schizophrenia and addictive disorders. American Journal on Addictions 1992;1:339-348 3) Rosenthal RN, Hellerstein DJ, Miner CR: Integrated services for treatment of schizophrenic substance abusers: demographics, symptoms and substance abuse patterns. Psychiatric Quarterly 1992;63:3-26 4) Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, Burrows L, Poster M, Cantillon M, Winston A: A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. American Journal of Psychiatry 1993;150:1169-1175 5) Hellerstein DJ, Rosenthal RN, Miner CR: Integrated outpatient treatment for substance-abusing schizophrenics: a prospective study. American Journal on Addictions 1995;4:33-42 6) Hellerstein DJ, Rosenthal RN, Pinsker H: Supportive therapy as the treatment model of choice. The Journal of Psychotherapy Practice and Research 1994;3:300-306 7) Hellerstein DJ, Little SAS: SSRI medications in the treatment of dysthymia and chronic depression. Journal of Serotonin Research 1994;1:181-187 8) Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U: Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. American Journal of Psychiatry 1997;154:390-395 9) Miner CR, Rosenthal RN, Hellerstein DJ: Through the revolving door: prediction of dropout in substance-abusing schizophrenic patients in outpatient group treatment, Archives of General Psychiatry 1997;54:706-712 10) Hellerstein DJ, Rosenthal RN, Pinsker H, Samstag LW, Muran JC, Winston A: A randomized prospective study comparing supportive and dynamic therapies: outcome and alliance. Journal of Psychiatric Practice and Research 1998;7:261-271 11) Rosenthal RN, Muran JC, Pinsker H, Hellerstein DJ, Winston A: Interpersonal change in brief supportive psychotherapy. J of Psychotherapy Practice and Research 1998;8:

Home  |  Psychiatric Practice  |  Research  |  Writing   |  About Dr. Hellerstein   |   Contact us

DJHell, © 1999, David Hellerstein